Core Viewpoint - The "Tongpu Shenzhou Wuyouxing" initiative, launched by a state-owned medical institution, aims to address the long-standing issue of cross-regional dialysis for patients, enabling them to travel and receive treatment seamlessly across different provinces [1][3][4]. Group 1: Background and Challenges - Nearly 90% of dialysis patients are confined within a 50-kilometer radius of their treatment centers, limiting their ability to travel for family visits or vacations [2]. - The challenges faced by dialysis patients include inconsistent treatment standards across regions, lack of information sharing between medical institutions, and barriers in medical insurance for cross-regional treatment [2][8]. Group 2: Implementation and Innovations - The initiative began with a professional meeting in November 2024, where a proposal was made to facilitate travel for dialysis patients, leading to the development of standardized documentation and processes for patient transfer [3][6]. - A comprehensive set of standardized documents was created within three weeks, covering all aspects from pre-travel assessments to emergency procedures, supported by a network of nearly 400 medical institutions across 28 provinces [3][6]. Group 3: Patient Experiences and Outcomes - As of December 15, 2024, the first patient, Aunt Jiang, successfully received dialysis treatment in Chengdu, demonstrating the effectiveness of the initiative in providing seamless care [4][5]. - By October 2025, the program had assisted 32 patients with 110 instances of cross-regional dialysis, achieving a 100% satisfaction rate among participants [5][6]. Group 4: Systemic Impact and Future Directions - The initiative represents a model for improving healthcare quality and accessibility, emphasizing the importance of life quality enhancement for patients beyond mere survival [7]. - The program's success highlights the potential for replicable pathways in addressing cross-regional medical collaboration challenges, with implications for broader healthcare reforms in China [7][8].

Group 1 - Jizhi Co., Ltd. plans to acquire at least 51% equity in Pumai Technology through cash payment, aiming to gain control over the company, which is a leading enterprise in the field of robot performance testing and calibration in China [1] - Yaxing Chemical's subsidiary intends to transfer 7.14% equity for 60 million yuan to another fund under the same control, indicating strategic investment movements within the same management group [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Sentai Co., Ltd.'s controlling shareholder plans to increase shareholding by at least 100 million yuan within 12 months, aiming to enhance confidence in the company's future [4] - Health元's subsidiary has received acceptance for the marketing authorization application of Lecanemab injection, which is intended for moderate to severe plaque psoriasis patients [5][11] - Sunshine Nuohuo has signed a technical development contract for the STC008 injection project, with a total payment of 500 million yuan, indicating significant investment in cancer treatment [6] Group 3 - Hunan YN has been designated as a delivery warehouse for lithium carbonate by the Guangzhou Futures Exchange, enhancing its position in the lithium market [7] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, although it faces risks in commercialization [8] - Yuandong Bio has received FDA approval for Methylene Blue injection, expanding its product portfolio in the U.S. market [10] Group 4 - Nanshan Aluminum has established a wholly-owned subsidiary in Hainan with an investment of 5 million yuan, focusing on high-end aluminum products [13] - ST Xifa plans to acquire 50% equity in Lhasa Beer, aiming for full ownership, with the transaction currently in the planning stage [14] - Hengrui Medicine's SHR-A1904 injection has been included in the list of breakthrough therapy products, indicating its potential in treating advanced gastric cancer [12] Group 5 - Chengdu Gas is planning to merge three subsidiaries, streamlining operations and enhancing efficiency [26] - Baoli Electric intends to invest 50 million yuan to establish a wholly-owned subsidiary focused on key equipment and solutions in energy storage [27] - Huadian International has successfully put the second unit of its Longkou Phase IV project into commercial operation, marking a significant milestone in its energy production capacity [34]

中国医药（600056）(600056.SH)发布公告，近日，公司下属全资子公司天方药业（600253）有限公司 (简称"天方药业")收到国家药品监督管理局核准签发的瑞舒伐他汀依折麦布片(I)《药品注册证书》。瑞 舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性高胆固醇血症(HoFH)。依折麦布与 瑞舒伐他汀钙两药联合可协同增效，能增加降血脂疗效并降低心血管事件。 ...

格隆汇12月24日丨中国医药(600056.SH)公布，近日，公司下属全资子公司天方药业有限公司收到国家 药监局核准签发的瑞舒伐他汀依折麦布片(I)《药品注册证书》。药品名称：瑞舒伐他汀依折麦布片(I)， 证书编号：2025S03793。 (三)截至本公告披露日，该药品累计投入约 2,439 万元人民币(未经审计)。 (二)国家药监局于 2024 年 8 月受理山东朗诺制药有限公司该药品的注册申请(受理号 CYHS2402864)， 2024 年 12 月受理天方药业有限公司该产品的药品上市许可持有人变更申请(受理号 CYHB2402147)。 (一)瑞舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性高胆固醇血症(HoFH)。依折麦 布与瑞舒伐他汀钙两药联合可协同增效，能增加降血脂疗效并降低心血管事件。 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-089 号 中国医药健康产业股份有限公司 关于子公司获得药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的瑞舒伐他汀依折麦布片（I）（以下简称"该 药品"）《药品注册证书》，现将有关情况公告如下： 一、注册证书基本信息 药品名称：瑞舒伐他汀依折麦布片（I） 受理号：CYHS2402864、CYHB2402147 证书编号：2025S03793 剂型：片剂 规格：每片含瑞舒伐他汀钙 10mg（按 C₂₂H₂₈FN₃O₆S 计）与依折麦布 10mg 二、药品其他相关情况 （一）瑞舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性 高胆固醇血症（HoFH）。依折麦布与瑞舒伐他汀钙两药联合可协同增效，能增 加降血脂疗效并降低心血管事件。 （二）国家药监局于 2024 年 8 ...

瑞舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性高胆固醇血症（HoFH）。依折麦 布与瑞舒伐他汀钙两药联合可协同增效，能增加降血脂疗效并降低心血管事件。 人民财讯12月24日电，中国医药（600056）12月24日公告，下属全资子公司天方药业（600253）收到国 家药品监督管理局核准签发的瑞舒伐他汀依折麦布片（I）《药品注册证书》。 ...

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has received the drug registration certificate for Rosuvastatin Ezetimibe Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating high cholesterol levels and familial hypercholesterolemia [1] Group 1 - The approved drug, Rosuvastatin Ezetimibe Tablets, is primarily used for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) [1] - The combination of Ezetimibe and Rosuvastatin calcium is expected to enhance lipid-lowering efficacy and reduce cardiovascular events [1]

Core Viewpoint - China Medical announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, received approval from the National Medical Products Administration for the drug Rosuvastatin and Ezetimibe Tablets, which may enhance the product line and accumulate experience, although sales may not meet expectations [1] Group 1: Product Approval - The drug is a combination of Rosuvastatin Calcium 10mg and Ezetimibe 10mg in tablet form [1] - The manufacturing company is Shandong Longnuo Pharmaceutical Co., Ltd. [1] Group 2: Financial Investment - The total investment in the drug up to the announcement date is approximately 24.39 million yuan [1] Group 3: Sales Projections - The projected sales for the drug in 2024 across three major terminals and six markets is approximately 1.46 million yuan (only for the original research) [1] - The projected sales for the first three quarters of 2025 is approximately 23.53 million yuan [1]

当前，医药零售行业正处于"从销售产品到提供健康服务"的转型关键期，合规化、数智化、服务化成为行业发展大方向。相关行业专家与领军者们带来前 沿洞察与实战方案：从行业数据、消费变迁到模式创新，为连锁经营突围提供清晰路径；剖析品牌赋能与终端流量转化的核心逻辑，为连锁品牌建设开辟 新视角。论坛总结指出，扬子江药业将持续以全域赋能计划与战略性产品线为支撑，与所有合作伙伴共建协同、共生、共赢的"和熙生态圈"，助力行业破 解"增收不增利"困局。 扬子晚报网12月24日讯(记者陈勇)"和风聚力，熙光筑梦。"12月22-23日，第十届健康中国医药连锁发展论坛(和熙论坛)在江苏泰州举办，来自全国各地的 医药零售合作伙伴齐聚一堂，以"健康营销营销健康健康人人人人健康"为共同信念，共探行业转型周期下的增长新机，见证"和熙生态圈"的深化升级。 记者在现场了解到，本次论坛由扬子江药业集团主办，是行业内连续十年深耕的品牌盛会。回望和熙论坛十载发展历程——从最初的政策研讨到模式创 新，再到如今的生态共建，数千家连锁伙伴携手走过的每一段旅程，都成为行业协同发展的珍贵印记。 扬子江药业集团党委书记、董事长、总裁徐浩宇发表致辞，立足行业新周期，分 ...

内容概况：医药包装机械是专门用于医药产品包装的机械设备，它在医药行业中扮演着至关重要的角 色，确保了药品从生产到消费者手中的安全性和有效性。这类机械涵盖了从简单的瓶装、袋装到复杂的 泡罩包装、双铝包装等多种包装形式，满足了不同药品对包装的特殊需求。医药包装机械的工作原理通 常基于自动化控制技术，通过精确的机械运动和智能的控制系统，实现药品的自动计量、填充、封口、 贴标等一系列包装流程。这些机械不仅提高了包装效率，还大大降低了人为因素对药品包装质量的影 响，确保了药品包装的准确性和一致性。近年来，随着老龄化加剧，以及人们消费水平的提升，医药市 场需求呈现增长趋势，带动了医药包装机械行业的迅猛发展，市场规模不断扩大。数据显示，中国医药 包装机械行业市场规模从2015年的27.6亿元增长至2024年的68.54亿元，年复合增长率为10.63%。未 来，随着医药产业向高端化、智能化与绿色化方向转型升级，以及药品安全监管与追溯体系不断完善， 中国医药包装机械行业将进一步朝着高精度、柔性化、集成化与数据互联的方向演进，在技术创新与市 场需求的双重驱动下实现更高质量的发展。 相关上市企业：春光智能（838810）、中信特钢 ...